Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.
AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.
The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.
